Enzo Biochem INC

Enzo Biochem, Inc. has completed its merger with Bethpage Merger Sub, Inc., becoming a wholly owned subsidiary of Bethpage Parent, Inc. and delisting its common stock.

Enzo Biochem, Inc. shareholders have approved the Agreement and Plan of Merger, paving the way for the company's acquisition.

Enzo Biochem, Inc. has entered into a definitive merger agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction, representing a significant premium to its recent trading price.

Enzo Biochem's Board of Directors is evaluating strategic options, including a potential sale, after receiving multiple acquisition inquiries.

Enzo Biochem, Inc. voluntarily delisted its common stock from the NYSE and began trading on the OTCQX under the symbol ENZB on April 21, 2025.

Enzo Biochem announces its intention to voluntarily delist from the New York Stock Exchange (NYSE) and move its trading to the OTCQX Best Market.

Enzo Biochem, a life sciences company, reported a wider quarterly operating loss and a significant revenue decline for the three months ended April 30, 2025, while announcing a strategic review and its voluntary delisting from the NYSE to OTCQX.

Enzo Biochem's Q2 2025 revenue decreased by 14% year-over-year, driven by lower market demand and timing of large order fulfillment, as the company continues to explore strategic alternatives.

Enzo Biochem's first quarter of fiscal year 2025 saw a decrease in revenue and a net loss, impacted by reduced customer orders and market challenges.

Enzo Biochem's Q3 2024 results show increased product revenue and reduced losses compared to the same period last year, following the sale of its clinical services business.

Enzo Biochem saw a revenue increase and reduced losses in the second quarter of fiscal year 2024, primarily driven by growth in its product segment and the sale of its clinical lab business.

Enzo Biochem's annual 10-K filing reveals a reduction in net losses and increased product revenue, driven by its Life Sciences division, following the sale of its clinical lab business.

Enzo Biochem Director Bradley Louis Radoff disposed of all his direct and indirect holdings in the company following its merger with Bethpage Parent, Inc. for $0.70 per share.

Enzo Biochem Director Steven J. Pully disposed of all his shares and restricted stock units following the company's merger, receiving $0.70 per share in cash.

ENZO Biochem's Chief Financial Officer, Patricia Eckert, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc.

Enzo Biochem Director Jonathan Couchman disposed of all his direct and indirect holdings in the company, totaling 605,134 shares and RSUs, following the completion of the merger with Bethpage Parent, Inc. at $0.70 per share.

ENZO BIOCHEM's CEO, Kara Cannon, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc. for $0.70 per share.

Director Bradley Louis Radoff of Enzo Biochem acquired 142,897 shares through restricted stock units, increasing his total holdings.

Enzo Biochem, Inc. shareholders are set to vote on a definitive merger agreement to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures, for $0.70 per share in cash, representing a significant premium over recent trading prices.

Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by an affiliate of Battery Ventures for $0.70 per share in cash, totaling approximately $37 million.

Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction valued at approximately $37 million, following a comprehensive strategic review.

Enzo Biochem will hold its 2024 Annual Meeting of Shareholders virtually on January 15, 2025, to vote on director elections, executive compensation, and auditor ratification.

Enzo Biochem Inc. has completed its merger, resulting in reporting persons Bradley L. Radoff and Radoff Family Foundation no longer holding any securities.

Battery Ventures affiliates have filed a Schedule 13D, disclosing beneficial ownership of 21.8% of Enzo Biochem, Inc. common stock through voting agreements supporting a merger with Bethpage Parent, Inc.

Harbert Discovery Fund and its affiliates have entered into a voting and support agreement to back the all-equity merger of Enzo Biochem Inc. with Bethpage Parent, Inc.

Bradley L. Radoff, a significant shareholder and director of Enzo Biochem Inc., has formally agreed to support the company's merger with Bethpage Parent, Inc. by committing his substantial shareholdings.

Beryl Capital Management and its affiliates have reported a 0% beneficial ownership in Enzo Biochem Inc., indicating a full divestment or reduction below reporting thresholds.

Beryl Capital Management and its affiliates have disclosed a significant beneficial ownership stake of 9.7% in Enzo Biochem Inc., totaling 5,069,789 shares of common stock.